BC Investments IV, linked to Bain Capital, is expected to sell a 2.4% stake in Emcure Pharmaceuticals. The sale will occur ...

Shares of Emcure Pharma shall be in focus during the trading session on Friday as Bain Capital-affiliated entity BC ...

As part of the deal Elena Lieskovska, a partner at Bain Capital, will join the board. She said: “We are thrilled to formally close our investment in The Openwork Partnership.

Bain Capital’s Ryan Cotton with 8 Vreeland Avenue in Totowa and 2401 E Linden Avenue in Linden, NJ (Bain Capital, Google Maps) May 8, 2025, 10:32 AM By Rich Bockmann Save article SHARE THIS ...

Adjusted EBITDA margin of 14.0% decreased 170 basis points from the prior year. Backlog of $233 million increased 1% compared to the prior year. Balance Sheet, Cash Flow and Capital Allocation 1 ...

Bain Capital, a private investment firm, completed the majority investment in Milacron and will partner with Milacron’s current owner, Hillenbrand, which will remain a significant investor in the ...

With the completion of the sale, Bain Capital now owns approximately 51% of Milacron and has full operational control, while Hillenbrand retains the remaining 49% stake.

Hillenbrand, Inc. HI announced that it has completed the previously announced sale of its majority interest in the Milacron injection molding and extrusion business (or Milacron) to Bain Capital ...

Bain Capital now owns a 51% share and has full operational control of Milacron, while Hillenbrand (NYSE: HI) maintains a 49% ownership stake.